Is p53 an independent prognostic factor in patients with laryngeal carcinoma?
BACKGROUND
Carcinoma of the true vocal cord represents the earliest clinically recognizable invasive malignancy in the head and neck region and provides a unique model for studying possible prognostic genetic markers. The aim of this study was to determine whether p53 overexpression correlated with tumor recurrence in a homogenous population of patients with early stage glottic carcinoma treated with radiotherapy alone.


METHODS
One hundred and fourteen patients with T1N0M0 squamous cell carcinoma of the glottis were treated with curative radiotherapy between 1976 and 1990. With a median follow-up of 6 years, actuarial local control was 80% with 23 local recurrences. Laryngeal biopsy specimens obtained prior to radiation therapy were analyzed retrospectively in 22 patients. Forty-five patients with local control were used as a control group. p53 overexpression indicating a mutated p53 gene was analyzed by immunohistochemistry using the mouse monoclonal antibody D0-7.


RESULTS
Approximately 82% of carcinomas that recurred locally expressed p53 compared with only 29% of those with local control (P < 0.001). No significant relation was noted between p53 expression and histologic grade. Intensity of staining did not predict tumor recurrence.


CONCLUSIONS
The authors believe that this case-controlled study demonstrated the role of p53 as an independent prognostic factor in patients with early stage glottic carcinoma.
Narayana
A
A
Department of Radiotherapy, Loyola University Medical Center, Maywood, Illinois, USA.
Vaughan
A T
AT
Gunaratne
S
S
Kathuria
S
S
Walter
S A
SA
Reddy
S P
SP
D000206:Actuarial Analysis; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor / Q000032:analysis / Q000235:genetics*; D001706:Biopsy; D002294:Carcinoma, Squamous Cell / Q000235:genetics / Q000473:pathology* / Q000532:radiotherapy; D016022:Case-Control Studies; D004396:Coloring Agents; D005260:Female; D005500:Follow-Up Studies; D015972:Gene Expression Regulation, Neoplastic; D016158:Genes, p53 / Q000235:genetics; D005931:Glottis / Q000473:pathology / Q000528:radiation effects; D006801:Humans; D007150:Immunohistochemistry; D007822:Laryngeal Neoplasms / Q000235:genetics / Q000473:pathology* / Q000532:radiotherapy; D008297:Male; D051379:Mice; D008875:Middle Aged; D009154:Mutation / Q000235:genetics; D009364:Neoplasm Recurrence, Local / Q000235:genetics / Q000473:pathology / Q000517:prevention & control; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D016159:Tumor Suppressor Protein p53 / Q000032:analysis / Q000235:genetics*
D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor; D004396:Coloring Agents; D016159:Tumor Suppressor Protein p53